Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
Top Page
Taysha Gene Therapies
(NASDAQ:TSHA)
Rating:54Neutral
Price Target:
$2.50
▼(-1.57%Downside)
Positive Factors
Clinical Effectiveness
TSHA's gene therapy program has shown promising results with continued patient benefits and no plateau in improvements, especially in high-dose treatments.
Commercial Opportunity
Dr. Lieberman appeared to find clinical data to date for TSHA-102 promising, and there is more positivity on the commercial opportunity for gene therapy in Rett syndrome.
Regulatory Flexibility
Announced FDA alignment for pivotal TSHA-102 trial shows continued flexibility.
Negative Factors
Competitive Risks
TSHA-102 has a lower procedural risk/burden compared to Neurogene's NGN-401.
Market Uncertainty
Bull/Bear cases related to potential commercial uptake and payor coverage.
Taysha Gene Therapies (TSHA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$669.52M
Dividend YieldN/A
Average Volume (3M)4.71M
Price to Earnings (P/E)―
Beta (1Y)1.94
Revenue Growth-48.97%
EPS Growth69.32%
CountryUS
Employees73
SectorHealthcare
Sector Strength55
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding261,530,400
10 Day Avg. Volume4,282,325
30 Day Avg. Volume4,706,490
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)104.67
Price to Sales (P/S)0.00
P/FCF Ratio-0.88
Enterprise Value/Market Cap0.11
Enterprise Value/Revenue1.86
Enterprise Value/Gross Profit9.88
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$8.35Price Target Upside228.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Taysha Gene Therapies Business Overview & Revenue Model
Company DescriptionTaysha Gene Therapies (TSHA) is a biotechnology company dedicated to developing and commercializing adeno-associated virus (AAV) gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). The company's mission is to eradicate severe genetic diseases through the power of gene therapy, with a focus on advancing a robust pipeline of therapies aimed at addressing significant unmet medical needs. Taysha leverages its proprietary AAV platform and is committed to transforming the lives of patients affected by debilitating genetic disorders.
How the Company Makes MoneyTaysha Gene Therapies primarily generates revenue through the development and commercialization of its gene therapy products. The company seeks to commercialize its therapies either directly or through strategic partnerships and collaborations with other pharmaceutical companies. Revenue can be derived from licensing agreements, milestone payments, and royalties on sales of approved therapies. Additionally, Taysha may receive funding through research and development collaborations or grants from government and non-profit organizations focused on advancing treatments for rare diseases. The company's financial performance is significantly influenced by the success of its clinical trials, regulatory approvals, and the commercial adoption of its therapies.
Taysha Gene Therapies Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q1-2025)
| % Change Since: 7.17%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Positive
The earnings call was predominantly positive, with significant regulatory progress and promising clinical data on TSHA-102 for Rett syndrome. The company is financially stable with a reduced net loss and decreased R&D expenses, although there was an increase in general and administrative costs.Q1-2025 Updates
Positive Updates
Progress in TSHA-102 Gene Therapy Program
Significant regulatory and clinical progress with TSHA-102 for Rett syndrome, including FDA alignment on pivotal trial design without the need for an end-of-phase meeting.
Positive Clinical Data
TSHA-102 has shown early clinical improvements and functional gains in pediatric, adolescent, and adult patients with Rett syndrome, which are unlikely in the untreated population.
Strong Financial Position
Taysha has $116.6 million in cash and cash equivalents, with cash resources expected to support operations into the fourth quarter of 2026.
Decreased R&D Expenses
Research and development expenses decreased by $5.1 million compared to the prior year, driven by reduced GMP batch activities.
Negative Updates
Increased General and Administrative Expenses
General and administrative expenses increased by $1.1 million due to higher compensation expenses and increases in legal and professional fees.
Net Loss
Net loss for the three months ended March 31, 2025, was $21.5 million, although this was an improvement from the previous year's loss of $24.1 million.
Company Guidance
During the Taysha Gene Therapies First Quarter 2025 earnings call, the company provided significant updates on their TSHA-102 gene therapy program for Rett syndrome. The company announced the completion of dosing for 10 patients in Part A of their REVEAL Phase 1/2 trials, with six patients receiving a high dose of TSHA-102. Encouragingly, TSHA-102 was generally well-tolerated across both high and low dose cohorts with no treatment-related serious adverse events or dose-limiting toxicities as of April 10, 2025. Taysha highlighted their alignment with the FDA on key elements of their pivotal Part B trial design, which eliminates the need for a formal end-of-phase meeting, potentially expediting study initiation. Financially, the company reported a net loss of $21.5 million for Q1 2025, with $116.6 million in cash reserves expected to support operations into Q4 2026. Overall, Taysha expressed confidence in the therapeutic potential of TSHA-102 and its path towards regulatory approval.Taysha Gene Therapies Financial Statement Overview
Summary
Taysha Gene Therapies is facing significant financial challenges, with ongoing losses, declining revenues, and negative cash flows highlighting liquidity constraints. The balance sheet indicates moderate leverage but low equity levels, signaling financial instability.Income Statement
Taysha Gene Therapies shows persistently negative net income and declining revenues, leading to weak profitability metrics. The company exhibits low EBIT and EBITDA margins and a negative revenue growth trajectory, indicating challenges in achieving operational efficiency and revenue generation.35
Negative
Balance Sheet
The balance sheet reflects a moderate debt-to-equity ratio and a declining equity base, suggesting financial strain. The equity ratio indicates limited shareholder equity relative to assets. The company's leverage and low equity position present financial stability risks.45
Neutral
Cash Flow
Cash flows are negative, driven by substantial operating losses. The cash flow to net income ratios are unfavorable, pointing to cash management challenges. Limited free cash flow growth indicates potential liquidity issues, despite consistent financing inflows.40
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 7.22M | 8.33M | 15.45M | 2.50M | 0.00 | 0.00 | Gross Profit |
| 7.22M | 8.33M | 15.45M | 15.00K | -492.00K | -9.00K | EBIT |
| -88.55M | -91.46M | -72.44M | -162.45M | -173.27M | -43.00M | EBITDA |
| -85.47M | -87.95M | -105.20M | -159.73M | -172.78M | -42.99M | Net Income Common Stockholders |
| -86.77M | -89.30M | -111.57M | -169.58M | -175.46M | -43.00M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 116.59M | 139.04M | 143.94M | 87.88M | 149.10M | 251.25M | Total Assets |
| 138.36M | 160.36M | 172.73M | 126.28M | 213.96M | 258.88M | Total Debt |
| 61.35M | 63.18M | 61.11M | 59.93M | 63.09M | 0.00 | Net Debt |
| -55.24M | -75.86M | -82.83M | -27.95M | -86.01M | -251.25M | Total Liabilities |
| 83.30M | 88.84M | 97.79M | 125.33M | 118.57M | 7.58M | Stockholders Equity |
| 55.06M | 71.53M | 74.94M | 949.00K | 95.38M | 251.30M |
| Cash Flow | Free Cash Flow | ||||
| -84.06M | -81.60M | -80.39M | -113.26M | -138.60M | -39.81M | Operating Cash Flow |
| -83.45M | -81.22M | -73.02M | -88.39M | -117.04M | -30.73M | Investing Cash Flow |
| -594.00K | -363.00K | -7.35M | -24.93M | -21.55M | -9.08M | Financing Cash Flow |
| 76.65M | 76.68M | 136.39M | 52.10M | 39.08M | 291.06M |
Taysha Gene Therapies Technical Analysis
Neutral
2.54
Price Trends
2.18
Positive
1.91
Positive
1.98
Positive
Market Momentum
0.10
Positive
50.33
Neutral
12.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSHA, the sentiment is Neutral. The current price of 2.54 is below the 20-day moving average (MA) of 2.73, above the 50-day MA of 2.18, and above the 200-day MA of 1.98, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 50.33 is Neutral, neither overbought nor oversold. The STOCH value of 12.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSHA.
Taysha Gene Therapies Risk Analysis
Taysha Gene Therapies disclosed 83 risk factors in its most recent earnings report. Taysha Gene Therapies reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Taysha Gene Therapies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $669.52M | ― | -159.34% | ― | -48.97% | 69.32% | |
54 Neutral | $5.34B | 3.27 | -45.10% | 3.30% | 16.80% | 0.02% | |
52 Neutral | $296.48M | 71.73 | 2.88% | ― | ― | 61.09% | |
47 Neutral | $270.44M | ― | -938.38% | ― | 38.82% | -645.78% | |
46 Neutral | $285.32M | ― | -41.59% | ― | ― | 0.42% | |
38 Underperform | $350.96M | ― | -48.22% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
TSHA
Taysha Gene Therapies
2.56
-0.41
-13.80%
RNAC
Cartesian Therapeutics
10.32
-11.44
-52.57%
OLMA
Olema Pharmaceuticals
4.19
-7.81
-65.08%
GLUE
Monte Rosa Therapeutics
4.82
1.28
36.16%
MBX
MBX Biosciences, Inc.
10.50
-11.15
-51.50%
Taysha Gene Therapies Corporate Events
Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Taysha Gene Therapies Approves Share Increase Amendment
Neutral
Jun 3, 2025
On June 2, 2025, Taysha Gene Therapies, Inc. held its annual meeting of stockholders where an amendment to increase the authorized number of shares of common stock from 400,000,000 to 700,000,000 was approved. Additionally, two directors were elected, and Deloitte & Touche LLP’s appointment as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions reflect the company’s strategic focus on expanding its capital structure and solidifying its governance framework.
The most recent analyst rating on (TSHA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Taysha Gene Therapies stock, see the TSHA Stock Forecast page.
Private Placements and Financing
Taysha Gene Therapies Announces Major Stock Offering
Neutral
May 29, 2025
On May 28, 2025, Taysha Gene Therapies announced an underwriting agreement to sell 46,868,687 shares of common stock and pre-funded warrants for 25,858,586 shares in a public offering, expecting to raise approximately $187.4 million. The offering, managed by Jefferies, BofA Securities, Piper Sandler, and Barclays, aims to fund the company’s operations and capital expenditures into 2028, with the closing expected on May 30, 2025.
The most recent analyst rating on (TSHA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Taysha Gene Therapies stock, see the TSHA Stock Forecast page.
Product-Related AnnouncementsBusiness Operations and Strategy
Taysha Gene Therapies Announces Pivotal Trial Design for TSHA-102
Positive
May 28, 2025
On May 28, 2025, Taysha Gene Therapies announced the design details for the pivotal Part B trial of TSHA-102 in Rett syndrome, following positive clinical data from Part A of the REVEAL trials. The trial, supported by the FDA, aims to assess developmental milestone gains in patients aged six and above, with the company planning to initiate the pivotal program in the third quarter of 2025. Additionally, Taysha suspended its ATM Prospectus related to $100 million of common stock but maintained the Sales Agreement in effect.
The most recent analyst rating on (TSHA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Taysha Gene Therapies stock, see the TSHA Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.